With a major breakthrough in psychedelic medicine, Compass Pathways' psilocybin-based therapy, COMP360, has delivered compelling Phase 3 results, sending shockwaves through the biopharma world and reigniting hope for patients with treatment-resistant depression. To unpack what this means for
The journey following a stem cell transplant can be fraught with complications, none more debilitating than chronic graft-versus-host disease, a condition where donor immune cells relentlessly attack the recipient's body. This review assesses Rezurock (belumosudil) as a critical therapeutic option
For individuals grappling with the relentless and often disfiguring effects of cutaneous lupus erythematosus, the path to effective treatment has been long and fraught with limited options, but a significant development from Biogen offers a new beacon of hope. The U.S. Food and Drug Administration
In the high-stakes world of biopharma, few stories are as compelling as the race to develop a successor to a multi-billion-dollar drug. We're joined today by Ivan Kairatov, a biopharma expert with deep experience in research, development, and the intricate dance between clinical data and commercial
The relentless cycle of flare-ups for those with severe Chronic Obstructive Pulmonary Disease has long demanded a more precise therapeutic weapon, a need the UK's health authorities have now addressed with a new approval. This review evaluates Nucala (mepolizumab), recently authorized by the MHRA
In the fast-evolving world of immunology, the race to develop a highly effective oral treatment for psoriasis has reached a fever pitch. With the recent success of Alumis's Phase 3 trials for envudeucitinib, the landscape is poised for a significant shift. We sat down with biopharma expert Ivan
